PMID- 22893018
OWN - NLM
STAT- MEDLINE
DCOM- 20130218
LR  - 20220331
IS  - 1432-1335 (Electronic)
IS  - 0171-5216 (Linking)
VI  - 139
IP  - 1
DP  - 2013 Jan
TI  - Individual risk assessment in bladder cancer patients based on a multi-marker 
      panel.
PG  - 49-56
LID - 10.1007/s00432-012-1297-9 [doi]
AB  - PURPOSE: To investigate whether a combined application of urine cytology (CYT) 
      and molecular markers for bladder cancer (BC) can predict tumor aggressiveness. 
      METHODS: The study comprised 2,113 patients who underwent urethrocystoscopy and 
      transurethral resection of the bladder. CYT, fluorescence in situ hybridization 
      (FISH), immunocytology (uCyt+) and nuclear matrix protein 22 test (NMP22-ELISA) 
      were performed. Results of the individual tests and of a multi-marker panel were 
      correlated with pT-stages and tumor grades. RESULTS: Five hundred and two of 
      2,113 (23.8 %) patients had BC. False-negative test rates of CYT (p < 0.001), 
      FISH (p = 0.01) and NMP22-ELISA (p = 0.05) were lower in patients with 
      muscle-invasive BC compared with patients with non-muscle-invasive BC. 
      Furthermore, false-negative rates of CYT (p < 0.001), FISH (p = 0.0002) and 
      NMP22-ELISA (p < 0.001) were lower in patients with G3/CIS compared with patients 
      with G1-G2 BC. In patients with evidence of tumor in urethrocystoscopy, the 
      presence of simultaneously positive CYT and NMP22 was associated with a 20-fold 
      risk for G3/CIS (p < 0.0001). CONCLUSIONS: This is the first study investigating 
      the combined use of four urine markers in addition to cystoscopy to predict tumor 
      aggressiveness. Our results indicate that combined application of urine markers 
      as an adjunct to cystoscopy may facilitate identification of patients harboring 
      high-grade tumors.
FAU - Todenhofer, Tilman
AU  - Todenhofer T
AD  - Department of Urology, University Hospital Tuebingen, Tuebingen, Germany.
FAU - Hennenlotter, Jorg
AU  - Hennenlotter J
FAU - Aufderklamm, Stefan
AU  - Aufderklamm S
FAU - Kuhs, Ursula
AU  - Kuhs U
FAU - Gakis, Georgios
AU  - Gakis G
FAU - Germann, Miriam
AU  - Germann M
FAU - Stenzl, Arnulf
AU  - Stenzl A
FAU - Schwentner, Christian
AU  - Schwentner C
LA  - eng
PT  - Journal Article
DEP - 20120815
PL  - Germany
TA  - J Cancer Res Clin Oncol
JT  - Journal of cancer research and clinical oncology
JID - 7902060
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Nuclear Proteins)
RN  - 0 (nuclear matrix protein 22)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/*analysis/*urine
MH  - *Cystectomy/methods
MH  - *Cystoscopy
MH  - Enzyme-Linked Immunosorbent Assay
MH  - False Negative Reactions
MH  - Female
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Grading
MH  - Neoplasm Invasiveness
MH  - Neoplasm Staging
MH  - Nuclear Proteins/*analysis
MH  - Odds Ratio
MH  - Predictive Value of Tests
MH  - Risk Assessment
MH  - Risk Factors
MH  - Sensitivity and Specificity
MH  - Urinary Bladder Neoplasms/chemistry/*pathology/surgery/*urine
EDAT- 2012/08/16 06:00
MHDA- 2013/02/19 06:00
CRDT- 2012/08/16 06:00
PHST- 2012/06/28 00:00 [received]
PHST- 2012/07/26 00:00 [accepted]
PHST- 2012/08/16 06:00 [entrez]
PHST- 2012/08/16 06:00 [pubmed]
PHST- 2013/02/19 06:00 [medline]
AID - 10.1007/s00432-012-1297-9 [doi]
PST - ppublish
SO  - J Cancer Res Clin Oncol. 2013 Jan;139(1):49-56. doi: 10.1007/s00432-012-1297-9. 
      Epub 2012 Aug 15.